Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Novartis and Michael Cohen, attorney to President Donald Trump, had a much deeper relationship than has been previously disclosed and was selling access to the White House, a new report issued by Senate Democrats alleges.
In a particularly large result, a St. Louis jury awarded almost $4.7 billion in total damages to 22 women and their families in a lawsuit against Johnson & Johnson.
President Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year. Other companies though have not followed suit and have gone through with price increases for their drugs.
The U.S. Drug Enforcement Agency is in the midst of readdressing cannabis following the regulatory approval of the first cannabinoid-based drug for the treatment of some epilepsy patients.
On June 11, 2018, FDA Commissioner Scott Gottlieb released a complementary framework for gene therapies, noting that in the last 12 months the agency has approved three different gene therapy products. “This reflects the rapid advancements in this field,” Gottlieb stated.
Schultz Chan, the former director of biostatistics at Cambridge-based Akebia Therapeutics and Songjiang Wang, a director of statistical programming at Merrimack Pharmaceuticals (MACK) were convicted of insider trading by a federal grand jury in Boston.
President Donald Trump was able to claim a victory in the drug pricing wars after Pfizer announced it would walk back the price increase of 40 prescription medications announced earlier this month.
The lawsuit and counter-lawsuits over the ouster of Rockwell Medical’s chief executive officer can be convoluted to follow, particularly as allegations are thrown around. BioSpace has put together a synopsis of the events.
President Donald Trump used the power of his Twitter feed to call out and condemn pharma giant Pfizer after that company increased the price of a number of its prescription medications by nearly 10 percent.
Legal battles are continuing between the Rockwell Medical Board of Directors and two senior executives who were fired earlier this year.